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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids was requested
to consider evaluations of ﬂavouring substances assessed since 2000 by the Joint FAO/WHO Expert
Committee on Food Additives (JECFA), and to decide whether further evaluation is necessary, as laid
down in Commission Regulation (EC) No 1565/20001. The present consideration concerns a group of
29 aliphatic secondary alcohols, ketones and related esters evaluated by JECFA at the 59th and 69th
meetings in 2002 and 2008. This revision is made due to the inclusion of nine additional substances
cleared for genotoxicity concern in FGE.205 Revision 1. The substances were evaluated through a
stepwise approach that integrates information on structure–activity relationships, intake from current
uses, toxicological threshold of concern and available data on metabolism and toxicity. The
Panel agrees with the application of the Procedure as performed by JECFA for all 29 substances
considered in this FGE. For all substances, the Panel concludes that there is ‘no safety concern at the
estimated levels of intake as ﬂavouring substances based on the MSDI approach’. For all 29
substances, the speciﬁcations for the materials of commerce have also been considered and found
adequate. Ten out of the 14 substances for which use levels became available exceed the modiﬁed
theoretical added maximum daily intake (mTAMDI) and more reliable exposure data are required to
ﬁnalise their evaluation. On the basis of such data, additional toxicological data might become
necessary. For 15 substances, use levels are needed to calculate the mTAMDIs in order to identify
those ﬂavouring substances that need more reﬁned exposure assessment to ﬁnalise the evaluation.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the Panel on Food Contact Materials, Enzymes,
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientiﬁc opinion to provide
scientiﬁc advice to the Commission on the implications for human health of chemically deﬁned
ﬂavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was
requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations
of ﬂavouring substances assessed since 2000, and to decide whether no further evaluation is
necessary, as laid down in Commission Regulation (EC) No 1565/2000.1 These ﬂavouring substances
are listed in the Union List, which was adopted by Commission Regulation (EU) No 872/20122 and its
consecutive amendments.
The Flavouring Group Evaluation 63 Revision 3 (FGE.63Rev3) deals with the consideration of 29
aliphatic secondary alcohols, ketones and related esters evaluated by JECFA at its 59th and 69th
meetings (JECFA, 2003, 2009b). Sixteen of the 29 substances [FL-no: 02.023, 02.099, 02.104, 02.136,
02.155, 02.252, 07.081, 07.099, 07.101, 07.102, 07.190, 07.247, 07.256, 09.281, 09.282 and 09.936]
possess an a,b-unsaturated structure which is considered a structural alert for genotoxicity. Therefore,
the 16 substances have been evaluated by the European Food Safety Authority (EFSA) in FGE.204,
FGE.206, FGE.205 and FGE.205Rev1, respectively, and the genotoxicity concern could be ruled out.
The Panel concluded that the 29 substances in the JECFA ﬂavouring group of aliphatic secondary
alcohols, ketones and related esters are structurally related to the group of 49 saturated and
unsaturated aliphatic secondary alcohols, ketones and esters of secondary alcohols and saturated
linear or branched-chain carboxylic acids evaluated in FGE.07Rev4.
The Panel agrees with the application of the Procedure as performed by JECFA for the 29
substances considered in this FGE.
For the 29 substances, the JECFA evaluation was based on maximised survey-derived daily intake
(MSDI) values derived from production ﬁgures from the European Union (EU). For all 29 substances,
the Panel agreed with the JECFA conclusion that, according to the Procedure, they are not expected to
be of safety concern when used as ﬂavouring substances based on the MSDI approach.
In order to determine whether the conclusion for the 29 JECFA-evaluated substances can be
applied to the materials of commerce, it is necessary to consider the available speciﬁcations. Adequate
speciﬁcations including complete purity criteria and identity became available for all the JECFA-
substances evaluated in this FGE.
Thus, for 29 JECFA-evaluated aliphatic secondary alcohols, ketones and related esters [FL-no:
02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.015, 07.069, 07.081, 07.099, 07.100, 07.101,
07.102, 07.114, 07.123, 07.151, 07.190, 07.240, 07.247, 07.249, 07.256, 09.281, 09.282, 09.657,
09.658, 09.923, 09.924, 09.925 and 09.936], the Panel agrees with the JECFA conclusion: ‘No safety
concern at current levels of intake when used as ﬂavouring agents, based on the MSDI approach’.
For 14 substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.081, 07.099, 07.101,
07.102, 07.190, 09.281, 09.282 and 09.936], industry has submitted use levels for normal and
maximum use. Based on these normal use levels, modiﬁed theoretical added maximum daily intake
(mTAMDI) values can be calculated. Four ﬂavouring substances [FL-no: 02.252, 07.099, 07.101 and
09.936] have mTAMDI intake estimates below the threshold of concern for their structural class. The
Panel noted that these four substances are evaluated via the A-side of the Procedure. For 10
substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 07.081, 07.102, 07.190, 09.281 and
09.282], the mTAMDI values are above the thresholds of concern for their structural class II of
540 lg/person per day. Therefore, for these 10 substances, more reliable exposure data are required
in order to ﬁnalise the evaluation. On the basis of such additional data, these ﬂavouring substances
should be reconsidered using the Procedure. Following this procedure, additional toxicological data
might become necessary. For the remaining 15 substances evaluated through the Procedure, use
levels are needed to calculate the mTAMDIs in order to identify those ﬂavouring substances that need
more reﬁned exposure assessment in order to ﬁnalise the evaluation.
1 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation
programme in application of Regulation (EC) No 2232/96. Ofﬁcial Journal of the European Communities L 180, 19.7.2000, 8–16.
2 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list
of ﬂavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council,
introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing
Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The use of ﬂavourings is regulated under Regulation (EC) No 1334/20083 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/2012.2 The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20001.
On 27 September 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF Panel) adopted an opinion on Flavouring Group Evaluation 205 (FGE.205):
Consideration of genotoxic potential on a,b-unsaturated aliphatic ketones with terminal double bonds
and precursors from chemical subgroup 1.2.2 of FGE.19.
The Panel concluded that for the two representative substances: oct-1-en-3-one [FL-no: 07.081]
and pent-1-en-3-one [FL-no: 07.102], the positive effects in the bacterial mutagenicity assays cannot
be overruled by one negative and one equivocal gene mutation test in mammalian cells. Accordingly,
an in vivo Comet assay on the ﬁrst site of contact (e.g. the stomach or duodenum) and on the liver
was requested for the most potent substance, pent-1-en-3-one [FL-no: 07.102]. As an alternative, a
transgenic animal assay would also be acceptable.
On 10 March 2015, the applicant submitted additional studies on the representative substances
[FL-no: 07.102] and [FL-no: 07.081]. These studies are intended to cover the substances in this group,
namely: FL-nos: 02.023, 02.099, 02.104, 02.131, 02.136, 02.155, 02.187, 07.161, 07.210, 09.281 and
09.282.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority (EFSA) to evaluate this
new information and, depending on the outcome, proceed to the full evaluation on the above
mentioned ﬂavouring substances in accordance with Commission Regulation (EC) No 1565/20001.
1.2. Interpretation of the Terms of Reference
The European Commission requests EFSA to carry out a safety assessment on the substances
oct-1-en-3-ol, pent-1-en-3-ol, hex-1-en-3-ol, dec-1-en-3-ol, 1-hepten-3-ol, oct-1-en-3-one, pent-1-en-
3-one, oct-1-en-3-yl acetate and oct-1-en-3-yl butyrate [FL-no: 02.023, 02.099, 02.104, 02.136,
02.155, 07.081, 07.102, 09.281 and 09.282], evaluated in FGE.205 Revision 1, in accordance with
Commission Regulation (EC) No 1565/20001.
2. Data and methodologies
The approach used by EFSA for safety evaluation of ﬂavouring substances is referred to in
Commission Regulation (EC) No 1565/20001, hereafter named the ‘EFSA Procedure’. This Procedure is
based on the opinion of the Scientiﬁc Committee on Food (SCF, 1999), which has been derived from
the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food Additives
(JECFA, 1995, 1996, 1997, 1999), hereafter named the ‘JECFA Procedure’. The CEF Panel compares
the JECFA evaluation of structurally related substances with the result of a corresponding EFSA
evaluation, focussing on speciﬁcations, intake estimations and toxicity data, especially genotoxicity
data. The evaluations by EFSA will conclude whether the ﬂavouring substances are of no safety
concern at their estimated levels of intake, whether additional data are required or whether certain
substances should not be put through the EFSA Procedure.
The following issues are of special importance.
3 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
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Intake
In its evaluation, the Panel as a default uses the ‘maximised survey-derived daily intake’ (MSDI)
approach to estimate the per capita intakes of the ﬂavouring substances in Europe.
In its evaluation, JECFA includes intake estimates based on the MSDI approach derived from both
European and USA production ﬁgures. The highest of the two MSDI ﬁgures is used in the evaluation
by JECFA. It is noted that in several cases, only the MSDI ﬁgures from the USA were available,
meaning that certain ﬂavouring substances have been evaluated by JECFA only on the basis of these
ﬁgures. For Register substances for which this is the case, the Panel will need the European Union
(EU) production ﬁgures in order to ﬁnalise the evaluation.
When the Panel examined the information provided by the European Flavour Industry on the use
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would
grossly underestimate the intake by regular consumers of products ﬂavoured at the use level reported
by industry, especially in those cases where the annual production values were reported to be small. In
consequence, the Panel had reservations about the data on use and use levels provided and the intake
estimates obtained by the MSDI approach. It is noted that JECFA, at its 65th meeting considered ‘how
to improve the identiﬁcation and assessment of ﬂavouring agents, for which the MSDI estimates may
be substantially lower than the dietary exposures that would be estimated from the anticipated
average use levels in foods’ (JECFA, 2006).
In the absence of more accurate information that would enable the Panel to make a more realistic
estimate of the intakes of the ﬂavouring substances, the Panel has decided also to perform an
estimate of the daily intakes per person using a modiﬁed ‘theoretical added maximum daily intake’
(mTAMDI) approach based on the normal use levels reported by industry.
As information on use levels for the ﬂavouring substances has not been requested by JECFA or has
not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the
mTAMDI approach for the substances evaluated by JECFA. The Panel will need information on use
levels in order to ﬁnalise the evaluation.
Threshold of 1.5 lg/person per day (Step B5) used by JECFA
JECFA uses the threshold of concern of 1.5 lg/person per day as part of the evaluation procedure:
The Committee noted that this value was based on a risk analysis of known carcinogens which
involved several conservative assumptions. The use of this value was supported by additional
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the
Committee, ﬂavouring substances for which insufﬁcient data are available for them to be evaluated
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 lg/person per day
would not be expected to present a safety concern. The Committee recommended that the Procedure
for the Safety Evaluation of Flavouring Agents used at the 46th meeting be amended to include the
last step on the right-hand side of the original Procedure (‘Do the condition of use result in an intake
greater than 1.5 lg per day?’) (JECFA, 1999).
In line with the opinion expressed by the Scientiﬁc Committee on Food (SCF, 1999), the Panel does
not make use of this threshold of 1.5 lg/person per day.
Genotoxicity
As reﬂected in the opinion of SCF (1999), the Panel has in its evaluation focussed on a possible
genotoxic potential of the ﬂavouring substances or of structurally related substances. Generally,
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro,
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided.
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through
the Procedure.
Speciﬁcations
Regarding speciﬁcations, the evaluation by the Panel could lead to a different opinion than that of
JECFA, since the Panel requests information on, e.g. isomerism.
Structural Relationship
In the consideration of the JECFA-evaluated substances, the Panel will examine the structural
relationship and metabolism features of the substances within the ﬂavouring group and compare this
with the corresponding Flavouring Group Evaluation (FGE).
Flavouring Group Evaluation 63 Revision 3
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2.1. History of the evaluation of the substances in the present FGE
At its 59th meeting, JECFA evaluated a group of 39 ﬂavouring substances consisting of aliphatic
secondary alcohols, ketones and related esters (JECFA, 2003). One of the JECFA-evaluated substances
is not in the Register [(E,R)-3,7-dimethyl-1,5,7-octatrien-3-ol (JECFA No: 1154)], and 25 substances
[FL-no: 02.023, 02.099, 02.102, 02.104, 02.136, 02.193, 07.044, 07.048, 07.081, 07.082, 07.099,
07.101, 07.102, 07.104, 07.105, 07.106, 07.107, 07.121, 07.138, 07.139, 07.177, 07.188, 07.244,
07.247 and 07.256] are a,b-unsaturated ketones or precursors for such, which have been considered
together with other a,b-unsaturated substances. FGE.63 therefore only dealt with 13 JECFA-evaluated
substances.
The ﬁrst revision of FGE.63, FGE.63Rev1, included the consideration of six additional substances
[FL-no: 02.252, 07.099, 07.190, 07.247, 07.256 and 09.936] evaluated by JECFA at their 59th and 69th
meetings. Furthermore, for six substances [FL-no: 07.069, 07.114, 09.657, 09.658, 09.923 and 09.925]
industry, European Flavour and Fragrance Association (EFFA), had submitted information on the
stereoisomeric composition, and for three substances, [FL-no: 07.069, 07.100 and 09.658], provided
the EU production volumes (EFFA, 2010).
The second revision of FGE.63, FGE.63Rev2, included the consideration of one additional
substance, 4-methylpent-3-en-2-one [FL-no: 07.101]. This substance is an a,b-unsaturated ketone and
was originally evaluated in FGE.204 (EFSA CEF Panel, 2012a) in which it was considered not to be of
concern with respect to genotoxicity.
FGE Adopted Link No. substances
63 07.07.2007 http://www.efsa.europa.eu/en/efsajournal/pub/706.htm 13
63Rev1 26.09.2012 http://www.efsa.europa.eu/en/efsajournal/pub/2900.htm 19
63Rev2 09.04.2013 https://www.efsa.europa.eu/en/efsajournal/pub/3188 20
63Rev3 30.11.2016 https://www.efsa.europa.eu/en/efsajournal/pub/4662 29
FGE: Flavouring Group Evaluation.
The present revision of FGE.63, FGE.63Rev3, includes the consideration of six additional substances
from the 59th meeting of JECFA, [FL-no: 02.023, 02.099, 02.104, 02.136, 07.081 and 07.102,] and
three substances [FL-no: 02.155, 09.281 and 09.282] from the 69th meeting of JECFA. These
substances are a,b-unsaturated secondary alcohols and ketones and were originally evaluated in
FGE.205 (EFSA CEF Panel, 2012c) and FGE.205Rev1 (EFSA CEF Panel, 2016) in which they were
considered to be of no concern with respect to genotoxicity. Therefore, these nine substances can be
evaluated in the present FGE using the Procedure. Additional speciﬁcations, use levels and tonnage
data have also become available for these substances and considered by the Panel (EFFA, 2016).
3. Assessment
3.1. Presentation of the substances in FGE.63Rev3
3.1.1. Substances evaluated by JECFA at the 59th and 69th meetings
3.1.1.1. JECFA status
This FGE deals with 29 JECFA-evaluated substances, 23 substances from the 59th meeting, 2002,
and six substances from the 69th meeting, 2008:
Of the 39 aliphatic secondary alcohols, ketones and related esters evaluated by JECFA at the 59th
meeting (JECFA, 2003), one of which is not in the Register ((E,R)-3,7-dimethyl-1,5,7-octatrien-3-ol
(JECFA No: 1154)) and one is no longer supported by industry (2-pentylbut-1-en-3-one [FL-no: 07.138]
(DG SANCO, 2012). Thirteen substances (all saturated aliphatic secondary alcohols, ketones and related
esters) were included in the ﬁrst release of FGE.63. The remaining 25 substances are a,b-unsaturated
ketones or precursors for such, which have been considered together with other a,b-unsaturated
substances with respect to a possible genotoxic potential. Ten of these 25 substances were evaluated
by EFSA for their genotoxic potential: three [FL-no: 07.099, 07.247 and 07.256] in FGE.206 (EFSA CEF
Panel, 2011), one (4-methylpent-3-en-2-one [FL-no: 07.101]) in FGE.204 (EFSA CEF Panel, 2012a) and
six [FL-no: 02.023, 02.099, 02.104, 02.136, 07.081 and 07.102] in FGE.205Rev1 (EFSA CEF Panel,
2016). For the remaining 14 substances [FL-no: 02.102, 02.139, 07.044, 07.048, 07.082, 07.104,
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07.105, 07.106, 07.107, 07.121, 07.139, 07.177, 07.188 and 07.244], a concern for genotoxicity could
not yet been ruled out in FGE.204 (EFSA CEF Panel, 2012a). Therefore, FGE.63Rev3 will address 23
substances that were evaluated by JECFA at their 59th meeting.
Of the 17 aliphatic secondary alcohols, ketones and related esters evaluated by JECFA at the 69th
meeting (JECFA, 2009b), ﬁve are not in the Register ((E,Z)-4-octen-3-one (JECFA No: 1843), (E)-2-
nonen-4-one (JECFA No: 1844), (E)-5-nonen-2-one (JECFA No: 1845), 10-undecen-2-one (JECFA No:
1849) and 8-nonen-2-one (JECFA No: 1851)). Three substances [FL-no: 02.155, 09.281 and 09.282]
have been evaluated in FGE.205Rev1 and three substances [FL-no: 02.252, 07.190 and 09.936] were
evaluated in FGE.206 (EFSA CEF Panel, 2011) for their possible genotoxic potential. The remaining six
substances [FL-no: 02.253, 07.097, 09.938, 07.239, 09.565 and 09.822] have been considered in
various other FGEs. Therefore, FGE.63Rev3 will address 6 substances that were evaluated by JECFA at
their 69th meeting.
3.1.1.2. EFSA considerations
For sixteen a,b-unsaturated ketones evaluated by JECFA at its 59th and 69th meetings (JECFA,
2003, 2009b), EFSA concluded that these were not of concern with respect to genotoxicity. Six
substances evaluated in FGE.206 and one substance evaluated in FGE.204 were included in
FGE.63Rev1 and FGE.63Rev2, respectively; nine substances evaluated in FGE.205Rev1 will be included
in the current revision of FGE.63Rev3. These, together with 13 aliphatic secondary alcohols, ketones
and related esters already considered in FGE.63, will thus comprise 29 ﬂavouring substances.
The Panel concluded that these 29 substances are structurally related to the group of 49 saturated
and unsaturated aliphatic secondary alcohols, ketones and esters of secondary alcohols and saturated
linear or branched-chain carboxylic acids evaluated by EFSA in Flavouring Group Evaluation 07,
Revision 4 (FGE.07Rev4) (EFSA CEF Panel, 2012b).
3.1.2. Isomers
3.1.2.1. JECFA status
Fifteen substances in the group of JECFA-evaluated aliphatic secondary alcohols, ketones and
related esters have a chiral centre [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.069,
09.281, 09.282, 09.657, 09.658, 09.923, 09.924, 09.925 and 09.936] and eight substances can exist
as geometrical isomers [FL-no: 02.252, 07.099, 07.114, 07.123, 07.190, 07.247, 07.256 and 09.936].
3.1.2.2. EFSA considerations
Flavouring substance [FL-no: 07.114] is a mixture of four geometrical isomers; however, no
quantitative information on the occurrence of these isomers is provided. The Panel considered the
available information on [FL-no: 07.114] adequate. For [FL-no: 07.123], the CASrn speciﬁes that it
consists of the E-isomer. The 13 chiral substances considered in this FGE are reported as racemates
(see Table 1).
3.1.3. Speciﬁcations
JECFA speciﬁcations are available for all 29 substances (JECFA, 2002, 2009a). See Table 1.
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For 29 substances evaluated by JECFA, intake data (MSDI) were available for the EU, see
Tables B.1 and C.2.
3.1.4.2. EFSA considerations
For all substances, industry has submitted production ﬁgures for the EU.
For 14 substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.081, 07.099, 07.101,
07.102, 07.190, 09.281, 09.282 and 09.936], industry has submitted normal and maximum use levels
(Flavour Industry, 2004; EFFA, 2016) (see Table C.1). Based on the normal use levels, mTAMDI values
can be calculated (see Table C.2), (EFSA, 2004). For 10 substances [FL-no: 02.023, 02.099, 02.104,
02.136, 02.155, 07.081, 07.102, 07.190, 09.281 and 09.282], the mTAMDI values are above the
threshold of concern for their structural class II of 540 lg/person per day. The remaining four
ﬂavouring substances [FL-no: 02.252, 07.099, 07.101 and 09.936] have mTAMDI intake estimates
below the threshold of concern for their structural class.
For 21 substances, use levels are needed in order to calculate the mTAMDIs.
The use levels and mTAMDI values are presented in Appendix C, Tables C.1 and C.2.
3.2. Genotoxicity
3.2.1. Genotoxicity studies – text taken4 from the 59th JECFA meeting and the
69th JECFA meeting (JECFA, 2003, 2009b)
Genotoxicity data were only available from the 59th meeting and only in vitro studies were
performed.
In vitro
Assays for reverse mutation were performed with 6-methylhept-5-en-2-one [FL-no: 07.015] and
6-methyl-3,5-heptadien-2-one [FL-no: 07.099]. There was no evidence of mutagenicity for 6-methylhept-
5-en-2-one at concentrations up to 380 lg/plate in TA98, TA100, TA1535 or TA1537 strains of Salmonella
Typhimurium (Florin et al., 1980). There was also no evidence of mutagenicity for 6-methyl-3,5-heptadien-
2-one at concentrations up to 370 lg/plate in the same strains (Florin et al., 1980).
For a summary of in vitro genotoxicity data considered by JECFA, see Table A.1.
3.2.2. Genotoxicity studies – text taken4 from EFSA FGE.07Rev4 (EFSA CEF
Panel, 2012b)
In vitro/In vivo
In vitro genotoxicity data have been reported for nine candidate substances. Negative results were
obtained in bacterial systems (+/ metabolic activation) with six candidate substances: one saturated
aliphatic acyclic secondary alcohol [FL-no: 02.183]; two saturated ketones [FL-no: 07.181 and 07.205];
two unsaturated ketones [FL-no: 07.198 and 07.262] and the ester isopropyl hexadecanoate [FL-no:
09.606]. Negative results were also obtained for the candidate substances pseudo-ionone [FL-no:
07.198], pentan-3-ol [FL-no: 02.077] and methyl-3-butan-2-one [FL-no: 07.178], the two-ﬁrst
mentioned being tested for chromosomal aberrations in mammalian cells and the latter for induction of
aneuploidy in yeast cells, respectively.
Induction of aneuploidy in yeast cells has been demonstrated for pentan-3-one [FL-no: 07.084].
The effect, measured only at high concentrations, approaching cytotoxic levels, can be considered to
be a threshold effect, not mediated by direct interaction with DNA. In addition, induction of aneuploidy
described in the paper is strongly potentiated by ice treatments included in the experimental protocol,
consistently with tubulin dissociation at low temperature in vitro; in the absence of this passage the
effect is very weak. Therefore, the effect could be considered as an effect occurring only under
unrealistic experimental conditions and the extrapolation of this result to the in vivo situation in
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE
has been removed.
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humans is questionable. Furthermore, it is well recognised that the relevance of fungal systems is
limited when induction of aneuploidy in mammalian systems has to be evaluated.
Pseudo-ionone [FL-no: 07.198] was considered with respect to genotoxicity in FGE.206 (EFSA CEF
Panel, 2011) where the Panel concluded that the data available ruled out the concern for genotoxicity.
Pseudo-ionone was tested in S. Typhimurium strains TA98, TA100, TA1535, TA1537 and TA102 in the
presence or absence of S9 and it is concluded that under the test conditions applied pseudo-ionone is
not mutagenic in bacteria. Pseudo-ionone was also evaluated in an in vitro micronucleus assay in
human peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in
the presence and absence of rat S9 fraction as an in vitro metabolising system. Under the conditions
of this study, pseudo-ionone was not clastogenic and/or aneugenic in cultured human lymphocytes.
In vitro genotoxicity data are also available for 10 supporting substances.
No evidence of mutagenicity obtained with bacterial and/or mammalian cells systems was reported
for: one saturated aliphatic acyclic secondary alcohol [FL-no: 02.079], ﬁve saturated [FL-no: 07.002,
07.050, 07.017, 07.053 and 07.122] and two unsaturated [FL-no: 07.015 and 07.099] aliphatic acyclic
ketones; two esters of an aliphatic acyclic secondary alcohol with linear aliphatic carboxylic acids [FL-no:
09.003 and 09.105]. 4-Methyl-2-pentanone [FL-no: 07.017] gave negative results also when tested for
chromosomal aberration activity.
Beside the negative results in in vitro bacterial point mutation tests, acetone [FL-no: 07.050]
showed no evidence of increased sister chromatid exchanges in several cytogenetic assays on different
mammalian cells, as well as no induction of chromosomal aberrations in Chinese hamster ovary cells
up to very high concentrations. Only one test on hamster lung ﬁbroblasts (conducted at an unspeciﬁed
acetone concentration) and an aneuploidy induction test on Saccharomyces cerevisiae (about 7%
acetone) gave positive results. However, these two studies were considered not relevant on the basis
of their poor quality and taking into account all the other negative genotoxicity results obtained with
acetone, including results in vivo (see below).
6-Methylhepta-3,5-dien-2-one [FL-no: 07.099] was considered with respect to genotoxicity in
FGE.206 (EFSA CEF Panel, 2011) where the Panel concluded that the data available ruled out the
concern for genotoxicity. 6-Methylhepta-3,5-dien-2-one was tested in S. Typhimurium strains TA98,
TA100, TA1535, TA1537 and TA102 in the presence or absence of S9 and it was concluded that under
the test conditions applied 6-methylhepta-3,5-dien-2-one is not mutagenic in bacteria. 6-Methylhepta-3,
5-dien-2-one was also evaluated in an in vitro micronucleus assay in human peripheral blood
lymphocytes for its ability to induce chromosomal damage or aneuploidy in the presence and absence of
rat S9 fraction as an in vitro metabolising system. Under the conditions of this study, 6-methylhepta-3,
5-dien-2-one was not clastogenic and/aneugenic in cultured human lymphocytes.
In vivo data are available for four supporting substances: one saturated aliphatic secondary alcohol
[FL-no: 02.079] and three saturated aliphatic ketones [FL-no: 07.017, 07.050 and 07.053], which
exhibited no genotoxic potential in the micronucleus cytogenetic assay at doses approaching the LD20
and the LD50 of the tested substances.
Conclusion on genotoxicity
On the basis of available data from in vitro and in vivo tests on candidate and supporting
substances, it can be concluded that the 49 candidate substances included in this group exhibit no
genotoxic potential.
For a summary of in vitro/in vivo genotoxicity data considered by EFSA, see Tables A.2 and A.3.
3.2.3. Genotoxicity studies – text taken4 from EFSA FGE.206 (EFSA CEF Panel,
2011)
Industry has submitted data concerning genotoxicity studies for 6-methylhepta-3,5-dien-2-one [FL-no:
07.099], a representative substance for FGE.19, subgroup 1.2.3 (EFSA, 2008a,b), evaluated in
FGE.206 (EFSA CEF Panel, 2011). In this revision of FGE.63, the data below are of importance for the
assessment of the genotoxic potential of six candidate substances [FL-no: 02.252, 07.099, 07.190,
07.247, 07.256 and 09.936], which have a structural alert for genotoxicity.
In vitro
6-Methylhepta-3,5-dien-2-one [FL-no: 07.099] was tested in S. Typhimurium strains TA98, TA100,
TA1535, TA1537 and TA102 in the presence or absence of S9. In the ﬁrst experiment, the
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concentrations tested were 1.6, 8, 40, 200, 1,000 and 5,000 lg/plate, and the plate incorporation
methodology was used. Severe toxicity was observed at 5,000 lg/plate in all strains (complete killing
of bacteria). No increase in revertant colonies was observed at any of the tested concentrations. In the
second experiment, the concentrations were 20.5, 51.2, 128, 320, 800, 2,000 and 5,000 lg/plate of
6-methylhepta-3,5-dien-2-one, and treatments in the presence of S9 were carried out according to the
pre-incubation method. In the absence of S9, the standard plate incorporation method was performed.
Slight thinning of the bacterial lawn or complete killing of the bacteria was observed in all strains at
2,000 and 5,000 lg/plate in the absence of S9. In the presence of S9, cytotoxicity was observed at
800 lg/plate and above and severe toxicity (complete killing of bacteria) was observed at 5,000 lg/plate
in all strains (Williams, 2009a). The study design complied with current recommendations (OECD 471;
GLP) and an acceptable top concentration was achieved. There was no evidence of mutagenic effect
induced by 6-methylhepta-3,5-dien-2-one in any of the strains, either in the absence or presence of
S9. No precipitation was observed at any tested concentrations (Williams, 2009a). It is concluded that
under the test conditions applied, 6-methylhepta-3,5-dien-2-one [FL-no: 07.099] is not mutagenic in
bacteria.
6-Methylhepta-3,5-dien-2-one [FL-no: 07.099] was evaluated in an in vitro micronucleus assay in
human peripheral blood lymphocytes for its ability to induce chromosomal damage or aneuploidy in
the presence and absence of rat S9 fraction as an in vitro metabolising system. The assay was
performed in accordance with the OECD 487 Guideline and in compliance with Good Laboratory
Practice (GLP). In a preliminary toxicity study, a wide range of concentrations up to 2,000 lg/mL of
6-methylhepta-3,5-dien-2-one was tested. The highest concentration used in the main test (450 lg/mL)
was limited by toxicity observed in the preliminary study. Cells were stimulated for 48 h with
phytohaemaglutinin to produce exponentially growing cells, and then treated for 3 h (followed by 21 h
recovery) with 0, 225, 325 or 450 lg/mL of 6-methylhepta-3,5-dien-2-one in the absence of S9 and 0,
225, 300 and 350 lg/mL in the presence of S9, respectively. The levels of toxicity (reduction in
replication index) at the top concentrations were 60% and 51% without and with S9, respectively. In a
parallel assay, cells were treated for 24 h with 0, 100, 120 or 150 lg/mL of 6-methylhepta-3,5-dien-2-one
in the absence of S9 with no recovery period. The top concentration induced 56% toxicity. There were
two replicate cultures per treatment, and 1,000 binucleate cells per replicate (i.e. 2,000 cells per dose)
were scored for micronuclei. No evidence of chromosomal damage or aneuploidy was observed by
increased levels of micronucleated binucleate cells (MNBN) in the presence or absence of S9 metabolic
activation (Whitwell, 2010). Under the conditions of this study, 6-methylhepta-3,5-dien-2-one was not
clastogenic and/aneugenic in cultured human lymphocytes.
Conclusion on genotoxicity
The Panel concluded that the in vitro genotoxicity data on 6-methylhepta-3,5-dien-2-one [FL-no:
07.099] do not indicate genotoxic potential.
As 6-methylhepta-3,5-dien-2-one [FL-no: 07.099] is a representative with respect to genotoxicity for
the following substances [FL-no: 02.252, 07.190, 07.247, 07.256 and 09.936], the genotoxicity concern
for these ﬁve substances can be ruled out and all six substances can be evaluated using the
Procedure.
For a summary of in vitro genotoxicity data considered by EFSA in FGE.206, see Table A.4.
3.2.4. Genotoxicity studies – text taken4 from EFSA FGE.204 (EFSA CEF Panel,
2012a)
Industry has submitted data concerning genotoxicity studies for 4-methylpent-3-en-2-one [FL-no:
07.101], a substance from FGE.19, subgroup 1.2.1 (EFSA, 2008a,b), evaluated in FGE.204 (EFSA CEF
Panel, 2012a). In this revision of FGE.63, the data below are of importance for the assessment of the
genotoxic potential of the candidate substance [FL-no: 07.101], which have a structural alert for
genotoxicity.
4-Methylpent-3-en-2-one [FL-no: 07.101] is considered negative in the Ames test with
S. Typhimurium tester strains consistent with the requirements for current regulatory guidelines.
Statistically signiﬁcant increase in the number of revertant colonies observed in tester strain TA1535 in
the absence of S9-mix metabolism in one experiment following treatment with 4-methylpent-3-en-2-
one are judged not biologically relevant, since they were not reproduced in the second experiment
(Williams, 2009b; Ballantyne, 2011b).
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Investigations at chromosome and genome levels in mammalian cells in vitro showed that
4-methylpent-3-en-2-one induced a small but statistically signiﬁcant increase in the frequency of MNBN
only in the presence of S9-mix metabolism following a 3-h treatment at the highest concentration
tested (981.4 lg/mL). However, only one replicate culture fell outside the historical vehicle control
range values. Following additional scoring of 2,000 erythrocytes, the resulting MNBN frequencies,
although still signiﬁcantly higher than concurrent vehicle control, lied within historical control range
values. In a second conﬁrmatory experiment (3-h treatment in the presence of S9-mix) performed at
concentrations lower than concentrations used in the previous experiment, due to an unexplained shift
of toxicity (comparable toxicity to those observed in the ﬁrst experiment, but at lower concentrations),
no signiﬁcant increase in MNBN frequencies was observed. Based on these results the Panel concluded
that 4-methylpent-3-en-2-one did not induce micronuclei in human peripheral blood lymphocytes, both
in the absence and presence of rat liver S9-mix metabolism (Stone, 2011).
Conclusion on genotoxicity
The Panel noted that for 4-methylpent-3-en-2-one [FL-no: 07.101], the data available showed that
it did not induce mutations in bacteria or micronuclei in human peripheral blood lymphocytes, neither
in the presence nor in the absence of rat liver S9-mix metabolic activation. Based on these ﬁndings,
the Panel concluded that 4-methylpent-3-en-2-one does not present a safety concern with respect to
genotoxicity and accordingly the ﬂavouring substance can be evaluated using the Procedure.
For a summary of in vitro genotoxicity data considered by EFSA in FGE.204, see Table A.5.
3.2.5. Genotoxicity studies – text taken4 from EFSA FGE.205Rev1 (EFSA CEF
Panel, 2016)
Industry has submitted genotoxicity data for oct-1-en-3-one [FL-no: 07.081] and pent-1-en-3-one
[FL-no: 07.102], which are substances from FGE.19, subgroup 1.2.2 (EFSA, 2008a,b), evaluated in
FGE.205Rev1 (EFSA CEF Panel, 2016). In this revision of FGE.63, the data below are of importance for
the assessment of the genotoxic potential of the candidate substances [FL-no: 07.081 and 07.102],
which have a structural alert for genotoxicity.
In response to the data request in FGE.205, industry has submitted in vivo data on both pent-1-en-
3-one [FL-no: 07.102] and oct-1-en-3-one [FL-no: 07.081].
Pent-1-en-3-one [FL-no: 07.102] tested in vivo in a combined micronucleus and comet assay did
not show genotoxic effects in either the liver or duodenum of treated rats. The negative results of the
bone marrow micronucleus assay are considered inconclusive because there is no evidence of bone
marrow exposure to the tested substance. However, as results of the in vitro micronucleus assay were
negative, no additional in vivo follow-up studies on clastogenicity and aneugenicity were needed. The
bacterial mutation assay provided for oct-1-en-3-one [FL-no: 07.081] conﬁrms the weak mutagenic
effect in bacteria shown in previous studies, but does not clarify the mechanism of action. The liver
comet assay is considered of limited validity due to low values of mean tail intensity and tail moment.
However, based on the data available on the most potent of the two representative substances for
subgroup 1.2.2, pent-1-en-3-one [FL-no: 07.102], the Panel concluded that there is no concern for
genotoxicity and accordingly nine substances in subgroup 1.2.2 [FL-no: 02.023, 02.099, 02.104,
02.136, 02.155, 07.081, 07.102, 09.281 and 09.282] can be evaluated using the Procedure.
For a summary of in vitro and in vivo genotoxicity data considered by EFSA in FGE.205 and
FGE.205Rev1, see Tables A.6 and A.7.
3.2.6. EFSA considerations on genotoxicity for substances in FGE.63Rev3
The Panel concluded that the data available do not preclude evaluation of the 29 aliphatic
secondary alcohols, ketones and related esters through the Procedure.
3.3. Application of the Procedure for the safety evaluation to 29
aliphatic secondary alcohols, ketones and related esters by JECFA
(2003, 2009b)
According to JECFA, eight of the substances belong to structural class I and 21 to structural class II
using the decision tree approach presented by Cramer et al. (1978).
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JECFA concluded all 29 aliphatic secondary alcohols, ketones and related esters at step A3 in the
JECFA Procedure, i.e. the substances are expected to be metabolised to innocuous products (step 2)
and the intakes for all substances are below the thresholds for their structural classes I and II (step A3).
In conclusion, JECFA evaluated all 29 substances as to be of no safety concern at current levels of
intake used as ﬂavouring agents based on the MSDI approach.
The evaluations of the 29 aliphatic secondary alcohols, ketones and related esters are summarised
in Table B.1: Summary of Safety Evaluation of Aliphatic Secondary Alcohols, Ketones and Related
Esters (JECFA, 2003, 2009b).
3.4. Application of the Procedure for the safety evaluation to 49
saturated and unsaturated aliphatic secondary alcohols, ketones
and esters of secondary alcohols and saturated linear or branched-
chain carboxylic acids by EFSA, FGE.07Rev4 (EFSA CEF Panel,
2012b)
Twenty-eight of the candidate substances [FL-no: 02.077, 02.124, 02.142, 02.148, 02.177, 02.182,
02.183, 02.190, 02.255, 07.084, 07.178, 07.239, 09.304, 09.323, 09.325, 09.328, 09.332, 09.386,
09.388, 09.391, 09.604, 09.605, 09.606, 09.608, 09.609, 09.676, 09.880 and 09.926] are classiﬁed
into structural class I, according to the decision tree approach presented by Cramer et al. (1978). The
remaining 21 candidate substances [FL-no: 02.145, 02.194, 02.211, 07.072, 07.150, 07.156, 07.157,
07.158, 07.160, 07.162, 07.181, 07.182, 07.185, 07.189, 07.198, 07.199, 07.201, 07.204, 07.205,
07.236 and 07.262], which are unsaturated aliphatic secondary alcohols or acyclic aliphatic saturated
or unsaturated ketones, are in structural class II.
Forty-eight substances were concluded at step A3 using the EFSA Procedure, i.e. the substances
are expected to be metabolised to innocuous products (step 2) and the estimated daily intakes for
these 48 substances are below the thresholds of concern for their structural classes, based on the
MSDI approach (step A3).
One candidate substance, 5-methylheptan-3-one [FL-no: 07.182], cannot be predicted to be
metabolised to innocuous products and therefore proceeds to step B3. The estimated daily intake of
this substance of 0.32 lg/capita per day does not exceed the threshold of concern for structural class
II (540 lg/person per day). Accordingly, the candidate substance proceeds to step B4 of the
Procedure. On the basis of a study on the neurotoxic effects of orally administered 5-methylheptan-3-
one [FL-no: 07.182] to male rats, a no observed adverse effect level (NOAEL) of 82 mg/kg body
weight (bw) per day was established (International Business Machines Corporation (IBM Corp.), 1989).
This NOAEL provides a margin of safety of 1.5 9 107 based on the estimated intake of the candidate
substance of 0.32 lg/capita per day. Based on results of the safety evaluation sequence, this
candidate substance does not pose a safety concern when used as ﬂavouring substance at the
estimated level of intake, based on the MSDI approach.
The stepwise evaluations of the 49 substances are summarised in Table B.2.
3.5. EFSA considerations
Two substances [FL-no: 09.281 and 09.282] were allocated to structural class I by JECFA, whereas
EFSA allocated these into structural class II.
Otherwise, the Panel agrees with the application of the Procedure as performed by JECFA for the
29 substances in the group of aliphatic secondary alcohols, ketones and related esters, and concluded
similar to JECFA that 29 ﬂavouring substances are not of safety concern when used as ﬂavouring
substances, based on the MSDI approach.
4. Conclusions
The FGE.63Rev3 deals with the consideration of 29 aliphatic secondary alcohols, ketones and
related esters evaluated by JECFA at its 59th and 69th meetings (JECFA, 2003, 2009b). Sixteen of the
29 substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.081, 07.099, 07.101,
07.102, 07.190, 07.247, 07.256, 09.281, 09.282 and 09.936] possess an a,b-unsaturated structure
which is considered a structural alert for genotoxicity. Therefore, the 16 substances have been
evaluated by EFSA in FGE.204, FGE.206 and FGE.205Rev1, respectively, and the genotoxicity concern
could be ruled out.
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The Panel concluded that the 29 substances in the JECFA ﬂavouring group of aliphatic secondary
alcohols, ketones and related esters are structurally related to the group of 49 saturated and
unsaturated aliphatic secondary alcohols, ketones and esters of secondary alcohols and saturated
linear or branched-chain carboxylic acids evaluated in FGE.07Rev4.
The Panel agrees with the application of the Procedure as performed by JECFA for the 29
substances considered in this FGE.
For all 29 substances, the Panel agreed with the JECFA conclusion that, according to the Procedure,
they are not expected to be of safety concern when used as ﬂavouring substances based on the MSDI
approach.
In order to determine whether the conclusion for the 29 JECFA-evaluated substances can be
applied to the materials of commerce, it is necessary to consider the available speciﬁcations. Adequate
speciﬁcations including complete purity criteria and identity are available for all the JECFA substances
evaluated in this FGE.
Thus, for the 29 JECFA-evaluated aliphatic secondary alcohols, ketones and related esters [FL-no:
02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.015, 07.069, 07.081, 07.099, 07.100, 07.101,
07.102, 07.114, 07.123, 07.151, 07.190, 07.240, 07.247, 07.249, 07.256, 09.281, 09.282, 09.657,
09.658, 09.923, 09.924, 09.925 and 09.936], the Panel agrees with the JECFA conclusion ˋNo safety
concern at estimated levels of intake as ﬂavouring substances, based on the MSDI approach0. For 14
substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 02.252, 07.081, 07.099, 07.101, 07.102,
07.190, 09.281, 09.282 and 09.936], industry has submitted use levels for normal and maximum use.
Based on these normal use levels, mTAMDI values can be calculated. Four ﬂavouring substances
[FL-no: 02.252, 07.099, 07.101 and 09.936] have mTAMDI intake estimates below the threshold of
concern for their structural class. The Panel noted that these four substances are evaluated via the
A-side of the Procedure. For 10 substances [FL-no: 02.023, 02.099, 02.104, 02.136, 02.155, 07.081,
07.102, 07.190, 09.281 and 09.282], the mTAMDI values are above the thresholds of concern for their
structural class II of 540 lg/person per day. Therefore, for these 10 substances more reliable exposure
data are required in order to ﬁnalise the evaluation. On the basis of such additional data, these
ﬂavouring substances should be reconsidered using the Procedure. Following this procedure, additional
toxicological data might become necessary. For the remaining 15 substances evaluated through the
Procedure, use levels are needed to calculate the mTAMDIs in order to identify those ﬂavouring
substances that need more reﬁned exposure assessment in order to ﬁnalise the evaluation.
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2) Beevers C, 2009. Reverse mutation in ﬁve histidine-requiring strains of Salmonella
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4) CMA (Chemical Manufacturers Association), 1990. Submission to EPA – mutagenicity test on
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study of 5-methyl-3-heptanone in the rat utilizing a functional observational battery and
neuropathology to detect neurotoxicity with cover letter 121589. EPA Doc ID 89-
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16) Stone V, 2011. Induction of micronuclei in cultured human peripheral blood lymphocytes.
4-Methylpent-3-en-2-one. Covance Laboratories Ltd. Study no. 8241438. August 23, 2011.
Unpublished report submitted by EFFA to FLAVIS Secretariat.
17) Whitwell J, 2010. Induction of micronuclei in cultured human peripheral blood lymphocytes.
6-Methylhepta-3,5-dien-2-one. Covance Laboratories Ltd, England. Study no. 8218055.
March 2010. Unpublished report submitted by EFFA to FLAVIS Secretariat.
18) Williams L, 2009a. Reverse mutation in ﬁve histidine-requiring strains of Salmonella
typhimurium. 6-Methyl hepta-3,5-dien-2-one. Covance Laboratories Ltd, England. Study no.
8200456. August 2009. Unpublished report submitted by EFFA to FLAVIS Secretariat.
19) Williams L, 2009b. Reverse mutation in ﬁve histidine-requiring strains of Salmonella
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Abbreviations
bw body weight
CAS Chemical Abstract Service
CASrn CAS register number
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO Chinese hamster ovary (cells)
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CoE Council of Europe
EFFA European Flavour and Fragrance Association
F female
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
FL-no FL-number
GLP Good Laboratory Practice




IR NMR infrared nuclear magnetic resonance spectroscopy
IR NMR MS infrared nuclear magnetic resonance mass spectroscopy
LD20 lethal dose, 20%
LD50 lethal dose, 50%; Median lethal dose
M male
MNBN micronucleated binucleate cells
MS mass spectrometry
MSDI maximised survey-derived daily intake
mTAMDI modiﬁed theoretical added maximum daily intake
ND not derived
NMR nuclear magnetic resonance
NMR MS nuclear magnetic resonance mass spectroscopy
NOAEL no observed adverse effect level
NR not reported
OECD Organisation for Economic Co-operation and Development
S9 metabolic activation
TAMDI theoretical added maximum daily intake
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